Shopping Cart 0
Cart Subtotal
USD 0

Endobronchial Valve System Market: Current Analysis and Forecast (2021-2027)

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4900

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 6860

Details

ENDOBRONCHIAL VALVE (EBV) TREATMENT, LIKE THE LUNG VOLUME REDUCTION SURGERY IS AIMED AT REMOVING HYPERINFLATED AND LESS FUNCTIONAL AREAS OF EMPHYSEMATOUS LUNGS. EBV IS LESS INVASIVE THAN SURGERY AND HAS A LOWER MORTALITY RATE. FURTHERMORE, ENDOBRONCHIAL VALVE IS ALSO MUCH CHEAPER THAN SURGERY. ENDOBRONCHIAL VALVE ALLOW EXPIRATION OF AIR FROM THE LOBE AND PREVENTS ITS RE-INFLATION. IN A COMPLETELY TREATED LOBE, EBV REDUCES THE LOBAR VOLUME AND EVENTUALLY A FULL LOBAR COLLAPSE LEADING TO THE REDUCTION OF LUNG HYPERINFLATION TO IMPROVEMENTS IN EXERCISE CAPACITY, BREATHLESSNESS, QUALITY OF LIFE AND PHYSICAL ACTIVITY.

EMPHYSEMA IS A CHRONIC OBSTRUCTIVE PULMONARY DISORDER, WHICH INVOLVES DAMAGE TO THE AIR SACS (ALVEOLI) IN THE LUNGS. IT IS A FORM OF CHRONIC LUNG DISORDER WHICH CAUSES DIFFICULTY IN BREATHING. THE EXHALATION OF AIRFLOW SLOWS DOWN DUE TO THE OVER-INFLAMMATION OF THE ALVEOLI. THE ENDOBRONCHIAL VALVE CLOSES DURING THE INHALATION TO STOP AIR FROM ENTERING THE DAMAGED PART OF THE LUNG. THESE VALVES REOPEN DURING EXHALATION TO LET OUT THE TRAPPED AIR TO REDUCE PRESSURE. ONE OF THE MAJOR CAUSES OF EMPHYSEMA IS SMOKING. ACCORDING TO STUDIES, SMOKERS ARE 6 TIMES MORE LIKELY TO HAVE EMPHYSEMA THAN NON-SMOKERS. IMPORTANT ADVANCEMENTS IN IDENTIFYING THE TREATMENT RESPONDERS HAVE BEEN MADE OVER THE YEARS. CRUCIAL STEPS IN THE SUCCESS OF TREATMENT INCLUDE: A FULLY OCCLUDED LOBE, PRESENCE OF AN EMPHYSEMATOUS TREATMENT TARGET LOBE, AND THE ABSENCE OF INTERLOBAR COLLATERAL VENTILATION. IT IS ESTIMATED THAT ONE BILLION COULD DIE FROM SMOKING IN THIS CENTURY, MAJORLY IN LOW-TO-MIDDLE INCOME COUNTRIES. SMOKING IS ONE THE LEADING RISKS FOR EARLY DEATH 8 MILLION PEOPLE DIED FROM SMOKING IN 2017. 15% OF GLOBAL DEATHS ARE ATTRIBUTED TO SMOKING.

BASED ON PRODUCT, THE MARKET IS BIFURCATED INTO DUCKBILL-SHAPED AND UMBRELLA-SHAPED ENDOBRONCHIAL VALVES. AMONGST PRODUCT, THE DUCKBILL-SHAPED ENDOBRONCHIAL VALVES SEGMENT WAS VALUED AT USD XX MILLION IN 2020 AND IS LIKELY TO REACH USD XX MILLION BY 2027 GROWING AT A CAGR OF XX% FROM 2021-2027. BASED ON END-USER THE ENDOBRONCHIAL VALVES MARKET IS SEGMENTED INTO HOSPITALS, CLINICAL RESEARCH CENTERS, AMBULATORY SURGERY CENTERS AND OTHERS. AMONGST END-USER, HOSPITALS ACCOUNTED FOR A MARKET VALUATION OF USD XX MILLION IN 2020 AND IS EXPECTED TO REACH USD XX MILLION BY THE YEAR 2027, AT A CAGR OF XX% OVER THE ANALYZED PERIOD.

FOR A BETTER UNDERSTANDING OF THE MARKET ADOPTION DETAILED ANALYSIS IS CONDUCTED FOR MAJOR REGIONS INCLUDING NORTH AMERICA (US, CANADA, AND REST OF NORTH AMERICA), EUROPE (GERMANY, FRANCE, ITALY, SPAIN, UK, AND REST OF EUROPE), ASIA-PACIFIC (CHINA, JAPAN, INDIA, AUSTRALIA, AND REST OF APAC), AND REST OF WORLD. NORTH AMERICA CONSTITUTES A MAJOR MARKET FOR THE ENDOBRONCHIAL VALVE SYSTEM INDUSTRY AND GENERATED REVENUE OF USD XX MILLION IN 2020 OWING TO THE PRESENCE OF WELL-ESTABLISHED PLAYERS IN THE REGION, RISING HEALTHCARE INVESTMENT BY THE COMPANIES, ETC.

SOME OF THE MAJOR PLAYERS OPERATING IN THE MARKET INCLUDE PULMONX CORPORATION (ZEPHYR), SPIRATION INC., MEDLUNG, NOVATECH AND OLYMPUS CORPORATION. SEVERAL M&A'S ALONG WITH PARTNERSHIPS HAVE BEEN UNDERTAKEN BY THESE PLAYERS TO BOOST THEIR PRESENCE IN DIFFERENT REGIONS.
READ MORE

Table Of Content

Scope

1 MARKET INTRODUCTION

1.1. MARKET DEFINITIONS

1.2. OBJECTIVE OF THE STUDY

1.3. LIMITATION

1.4. STAKE HOLDERS

1.5. CURRENCY USED IN REPORT

1.6. SCOPE OF THE ENDOBRONCHIAL VALVE SYSTEM MARKET STUDY

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. RESEARCH METHODOLOGY FOR THE ENDOBRONCHIAL VALVE SYSTEM MARKET

2.1.1. MAIN OBJECTIVE OF THE ENDOBRONCHIAL VALVE SYSTEM MARKET

3 INDUSTRY PERFORMANCE

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 MARKET INSIGHTS BY PROCDUCT

6.1. DUCKBILL-SHAPED ENDOBRONCHIAL VALVES

6.2. UMBRELLA-SHAPED ENDOBRONCHIAL VALVES

7 MARKET INSIGHTS BY END-USER

7.1. HOSPITALS

7.2. CLINICAL RESEARCH CENTERS

7.3. AMBULATORY SURGERY CENTERS

7.4. OTHERS

8 MARKET INSIGHTS BY REGION

8.1. NORTH AMERICA ENDOBRONCHIAL VALVE SYSTEM MARKET

8.1.1. UNITED STATES OF AMERICA

8.1.2. CANADA

8.1.3. REST OF NORTH AMERICA

8.2. EUROPE ENDOBRONCHIAL VALVE SYSTEM MARKET

8.2.1. UNITED KINGDOM

8.2.2. GERMANY

8.2.3. FRANCE

8.2.4. SPAIN

8.2.5. ITALY

8.2.6. REST OF EUROPE

8.3. ASIA-PACIFIC ENDOBRONCHIAL VALVE SYSTEM MARKET

8.3.1. CHINA

8.3.2. JAPAN

8.3.3. INDIA

8.3.4. AUSTRALIA

8.3.5. REST OF ASIA-PACIFIC

8.4. REST OF THE WORLD ENDOBRONCHIAL VALVE SYSTEM MARKET

9 LEGAL AND REGULATORY FRAMEWORK

10 DEMAND AND SUPPLY SIDE ANALYSIS

10.1. DEMAND SIDE ANALYSIS

10.2. SUPPLY SIDE ANALYSIS

10.2.1. TOP PRODUCT LAUNCHES

10.2.2. TOP BUSINESS PARTNERSHIPS

10.2.3. TOP BUSINESS EXPANSIONS, INVESTMENTS AND DIVESTITURES

10.2.4. TOP MERGER AND ACQUISITIONS

11 VALUE CHAIN ANALYSIS

12 ENDOBRONCHIAL VALVE SYSTEM MARKET TRENDS & INSIGHTS

13 ENDOBRONCHIAL VALVE SYSTEM MARKET DYNAMICS

13.1. DRIVERS

13.2. CHALLENGES

13.3. IMPACT ANALYSIS

13.4. OPPORTUNITY

14 COMPETITIVE SCENARIO

14.1. ENDOBRONCHIAL VALVE SYSTEM MARKET SHARE, BY COMPANY 2020

15 COMPANY PROFILED

15.1. PULMONX CORPORATION (ZEPHYR)

15.2. SPIRATION INC

15.3. MEDLUNG

15.4. NOVATECH

15.5. OLYMPUS CORPORATION

16 DISCLAIMER

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

PULMONX CORPORATION (ZEPHYR)

SPIRATION INC.

MEDLUNG

NOVATECH

OLYMPUS CORPORATION

Company Profile

Company Profile Title

ENDOBRONCHIAL VALVE (EBV) TREATMENT, LIKE THE LUNG VOLUME REDUCTION SURGERY IS AIMED AT REMOVING HYPERINFLATED AND LESS FUNCTIONAL AREAS OF EMPHYSEMATOUS LUNGS. EBV IS LESS INVASIVE THAN SURGERY AND HAS A LOWER MORTALITY RATE. FURTHERMORE, ENDOBRONCHIAL VALVE IS ALSO MUCH CHEAPER THAN SURGERY. ENDOBRONCHIAL VALVE ALLOW EXPIRATION OF AIR FROM THE LOBE AND PREVENTS ITS RE-INFLATION. IN A COMPLETELY TREATED LOBE, EBV REDUCES THE LOBAR VOLUME AND EVENTUALLY A FULL LOBAR COLLAPSE LEADING TO THE REDUCTION OF LUNG HYPERINFLATION TO IMPROVEMENTS IN EXERCISE CAPACITY, BREATHLESSNESS, QUALITY OF LIFE AND PHYSICAL ACTIVITY.

EMPHYSEMA IS A CHRONIC OBSTRUCTIVE PULMONARY DISORDER, WHICH INVOLVES DAMAGE TO THE AIR SACS (ALVEOLI) IN THE LUNGS. IT IS A FORM OF CHRONIC LUNG DISORDER WHICH CAUSES DIFFICULTY IN BREATHING. THE EXHALATION OF AIRFLOW SLOWS DOWN DUE TO THE OVER-INFLAMMATION OF THE ALVEOLI. THE ENDOBRONCHIAL VALVE CLOSES DURING THE INHALATION TO STOP AIR FROM ENTERING THE DAMAGED PART OF THE LUNG. THESE VALVES REOPEN DURING EXHALATION TO LET OUT THE TRAPPED AIR TO REDUCE PRESSURE. ONE OF THE MAJOR CAUSES OF EMPHYSEMA IS SMOKING. ACCORDING TO STUDIES, SMOKERS ARE 6 TIMES MORE LIKELY TO HAVE EMPHYSEMA THAN NON-SMOKERS. IMPORTANT ADVANCEMENTS IN IDENTIFYING THE TREATMENT RESPONDERS HAVE BEEN MADE OVER THE YEARS. CRUCIAL STEPS IN THE SUCCESS OF TREATMENT INCLUDE: A FULLY OCCLUDED LOBE, PRESENCE OF AN EMPHYSEMATOUS TREATMENT TARGET LOBE, AND THE ABSENCE OF INTERLOBAR COLLATERAL VENTILATION. IT IS ESTIMATED THAT ONE BILLION COULD DIE FROM SMOKING IN THIS CENTURY, MAJORLY IN LOW-TO-MIDDLE INCOME COUNTRIES. SMOKING IS ONE THE LEADING RISKS FOR EARLY DEATH 8 MILLION PEOPLE DIED FROM SMOKING IN 2017. 15% OF GLOBAL DEATHS ARE ATTRIBUTED TO SMOKING.

BASED ON PRODUCT, THE MARKET IS BIFURCATED INTO DUCKBILL-SHAPED AND UMBRELLA-SHAPED ENDOBRONCHIAL VALVES. AMONGST PRODUCT, THE DUCKBILL-SHAPED ENDOBRONCHIAL VALVES SEGMENT WAS VALUED AT USD XX MILLION IN 2020 AND IS LIKELY TO REACH USD XX MILLION BY 2027 GROWING AT A CAGR OF XX% FROM 2021-2027. BASED ON END-USER THE ENDOBRONCHIAL VALVES MARKET IS SEGMENTED INTO HOSPITALS, CLINICAL RESEARCH CENTERS, AMBULATORY SURGERY CENTERS AND OTHERS. AMONGST END-USER, HOSPITALS ACCOUNTED FOR A MARKET VALUATION OF USD XX MILLION IN 2020 AND IS EXPECTED TO REACH USD XX MILLION BY THE YEAR 2027, AT A CAGR OF XX% OVER THE ANALYZED PERIOD.

FOR A BETTER UNDERSTANDING OF THE MARKET ADOPTION DETAILED ANALYSIS IS CONDUCTED FOR MAJOR REGIONS INCLUDING NORTH AMERICA (US, CANADA, AND REST OF NORTH AMERICA), EUROPE (GERMANY, FRANCE, ITALY, SPAIN, UK, AND REST OF EUROPE), ASIA-PACIFIC (CHINA, JAPAN, INDIA, AUSTRALIA, AND REST OF APAC), AND REST OF WORLD. NORTH AMERICA CONSTITUTES A MAJOR MARKET FOR THE ENDOBRONCHIAL VALVE SYSTEM INDUSTRY AND GENERATED REVENUE OF USD XX MILLION IN 2020 OWING TO THE PRESENCE OF WELL-ESTABLISHED PLAYERS IN THE REGION, RISING HEALTHCARE INVESTMENT BY THE COMPANIES, ETC.

SOME OF THE MAJOR PLAYERS OPERATING IN THE MARKET INCLUDE PULMONX CORPORATION (ZEPHYR), SPIRATION INC., MEDLUNG, NOVATECH AND OLYMPUS CORPORATION. SEVERAL M&A'S ALONG WITH PARTNERSHIPS HAVE BEEN UNDERTAKEN BY THESE PLAYERS TO BOOST THEIR PRESENCE IN DIFFERENT REGIONS.
READ MORE

Scope

1 MARKET INTRODUCTION

1.1. MARKET DEFINITIONS

1.2. OBJECTIVE OF THE STUDY

1.3. LIMITATION

1.4. STAKE HOLDERS

1.5. CURRENCY USED IN REPORT

1.6. SCOPE OF THE ENDOBRONCHIAL VALVE SYSTEM MARKET STUDY

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. RESEARCH METHODOLOGY FOR THE ENDOBRONCHIAL VALVE SYSTEM MARKET

2.1.1. MAIN OBJECTIVE OF THE ENDOBRONCHIAL VALVE SYSTEM MARKET

3 INDUSTRY PERFORMANCE

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 MARKET INSIGHTS BY PROCDUCT

6.1. DUCKBILL-SHAPED ENDOBRONCHIAL VALVES

6.2. UMBRELLA-SHAPED ENDOBRONCHIAL VALVES

7 MARKET INSIGHTS BY END-USER

7.1. HOSPITALS

7.2. CLINICAL RESEARCH CENTERS

7.3. AMBULATORY SURGERY CENTERS

7.4. OTHERS

8 MARKET INSIGHTS BY REGION

8.1. NORTH AMERICA ENDOBRONCHIAL VALVE SYSTEM MARKET

8.1.1. UNITED STATES OF AMERICA

8.1.2. CANADA

8.1.3. REST OF NORTH AMERICA

8.2. EUROPE ENDOBRONCHIAL VALVE SYSTEM MARKET

8.2.1. UNITED KINGDOM

8.2.2. GERMANY

8.2.3. FRANCE

8.2.4. SPAIN

8.2.5. ITALY

8.2.6. REST OF EUROPE

8.3. ASIA-PACIFIC ENDOBRONCHIAL VALVE SYSTEM MARKET

8.3.1. CHINA

8.3.2. JAPAN

8.3.3. INDIA

8.3.4. AUSTRALIA

8.3.5. REST OF ASIA-PACIFIC

8.4. REST OF THE WORLD ENDOBRONCHIAL VALVE SYSTEM MARKET

9 LEGAL AND REGULATORY FRAMEWORK

10 DEMAND AND SUPPLY SIDE ANALYSIS

10.1. DEMAND SIDE ANALYSIS

10.2. SUPPLY SIDE ANALYSIS

10.2.1. TOP PRODUCT LAUNCHES

10.2.2. TOP BUSINESS PARTNERSHIPS

10.2.3. TOP BUSINESS EXPANSIONS, INVESTMENTS AND DIVESTITURES

10.2.4. TOP MERGER AND ACQUISITIONS

11 VALUE CHAIN ANALYSIS

12 ENDOBRONCHIAL VALVE SYSTEM MARKET TRENDS & INSIGHTS

13 ENDOBRONCHIAL VALVE SYSTEM MARKET DYNAMICS

13.1. DRIVERS

13.2. CHALLENGES

13.3. IMPACT ANALYSIS

13.4. OPPORTUNITY

14 COMPETITIVE SCENARIO

14.1. ENDOBRONCHIAL VALVE SYSTEM MARKET SHARE, BY COMPANY 2020

15 COMPANY PROFILED

15.1. PULMONX CORPORATION (ZEPHYR)

15.2. SPIRATION INC

15.3. MEDLUNG

15.4. NOVATECH

15.5. OLYMPUS CORPORATION

16 DISCLAIMER

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

PULMONX CORPORATION (ZEPHYR)

SPIRATION INC.

MEDLUNG

NOVATECH

OLYMPUS CORPORATION